MID1IP1

Across TCGA pan-cancer cohorts, MID1IP1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MID1IP1 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MID1IP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MID1IP1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where MID1IP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.533	0.796	.009	19	view →
LUAD	OS	Tertile	II,III,IV	0.893	0.334	.002	16	view →
LSCC	OS	Median	All	0.709	0.853	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MID1IP1–HNSC (OS)

Open the HNSC breakdown →